Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

8,100

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

May 25, 2029

Study Completion Date

May 25, 2029

Conditions
Papillomavirus Infections
Interventions
BIOLOGICAL

9vHPV Vaccine

9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection

OTHER

Placebo

Sterile saline solution administered as a 0.5 mL IM injection

Trial Locations (34)

100069

Beijing Youan Hospital ( Site 0001), Beijing

110001

The first affiliated hospital of China medical university ( Site 0041), Shenyang

110031

Liaoning University of Traditional Chinese Medicine Affiliated Hospital ( Site 0048), Shenyang

300192

Tianjin Second People's Hospital ( Site 0004), Tianjin

325000

Zhejiang University School of Medicine - Affiliated Wenzhou Traditional Chinese Medicine Hospital (W, Wenzhou

400010

The Second Affiliated Hospital Chongqing Medical University ( Site 0052), Chongqing

400036

Chongqing Public Health Medical Center ( Site 0003), Chongqing

410005

Hunan Provincial Center for Disease Control and Prevention ( Site 0040), Changsha

410013

The Third Xiangya Hospital of Central South University ( Site 0033), Changsha

417000

Loudi Disease Prevention and Control Center Zhiyebing Prevention And Treatment Hospital ( Site 0015), Louxing District

426100

Qiyang Center for Disease Control and Prevention ( Site 0014), Yongzhou

430022

Wuhan Union Hospital ( Site 0032), Wuhan

510515

Southern Medical University Nanfang Hospital-Center for Drug Clinical Research ( Site 0031), Guangzhou

518053

The University of Hong Kong - Shenzhen Hospital ( Site 0049), Shenzhen

545400

Center for Disease Control and Prevention of Rong An ( Site 0046), Liuzhou

621000

Mianyang Center for Disease Control and Prevention ( Site 0007), Mianyang

621100

Santai County Center for Disease Control and Prevention ( Site 0008), Mianyang

635100

Dazhu Disease Prevention and Control Center ( Site 0010), Dazhou

638399

Yuechi Disease Prevention and Control Center ( Site 0009), Guang’an

641000

Neijiang Center for Disease Control and Prevention ( Site 0011), Neijiang

650032

First Affiliated Hospital of Kunming Medical University ( Site 0051), Kunming

650111

Yunnan Provincial Infectious Disease Hospital ( Site 0042), Kunming

671600

Binchuan County Center for Disease Control and Prevention ( Site 0022), Dali

672100

Xiangyun County Center for Disease Control and Prevention ( Site 0021), Dali

730000

The First Hospital of Lanzhou University ( Site 0034), Lanzhou

2100003

The Second Hospital of Nanjing (Tangshan Branch) ( Site 0028), Nanjing

Unknown

Liucheng County Centers for Disease Control and Prevention ( Site 0045), Liuzhou

Xiangtan Disease Prevention and Control Center ( Site 0030), Xiangtan

Xiangxiang Disease Prevention and Control Center ( Site 0016), Xiangxiang

Tianjin People' s Hospital ( Site 0038), Tianjin

043700

Yuanqu Center for Disease Control and Prevention ( Site 0019), Yuncheng

044000

Yanhu Center for Disease Control and Prevention of Yuncheng ( Site 0018), Yuncheng

044599

Yongji Center for Disease Control and Prevention ( Site 0026), Yuncheng

044600

Ruicheng Center for Disease Control and Prevention ( Site 0025), Yuncheng

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY